Brian Higgins
Overview
Explore the profile of Brian Higgins including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
3341
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ryou H, Sirinukunwattana K, Wood R, Aberdeen A, Rittscher J, Weinberg O, et al.
Hemasphere
. 2024 Jun;
8(6):e105.
PMID: 38884042
No abstract available.
2.
Verstovsek S, Talpaz M, Wadleigh M, Isidori A, Te Boekhorst P, Savona M, et al.
Haematologica
. 2024 Jan;
109(6):1977-1983.
PMID: 38268448
No abstract available.
3.
Scott M, Liu W, Mitchell R, Clarke C, Kinstrie R, Warren F, et al.
Nat Commun
. 2024 Jan;
15(1):651.
PMID: 38246924
Whilst it is recognised that targeting self-renewal is an effective way to functionally impair the quiescent leukaemic stem cells (LSC) that persist as residual disease in chronic myeloid leukaemia (CML),...
4.
Verstovsek S, Foltz L, Gupta V, Hasserjian R, Manshouri T, Mascarenhas J, et al.
Haematologica
. 2023 May;
108(10):2730-2742.
PMID: 37165840
Pentraxin 2 (PTX-2; serum amyloid P component), a circulating endogenous regulator of the inflammatory response to tissue injury and fibrosis, is reduced in patients with myelofibrosis (MF). Zinpentraxin alfa (RO7490677,...
5.
Mascarenhas J, Passamonti F, Burbury K, El-Galaly T, Gerds A, Gupta V, et al.
Blood Adv
. 2021 Dec;
6(4):1162-1174.
PMID: 34933330
Idasanutlin, an MDM2 antagonist, showed clinical activity and a rapid reduction in JAK2 V617F allele burden in patients with polycythemia vera (PV) in a phase 1 study. This open-label phase...
6.
Salmon A, Cooper R, Chen M, Higgins B, Cava J, Chen N, et al.
Biomed Opt Express
. 2021 Jul;
12(6):3142-3168.
PMID: 34221651
To mitigate the substantial post-processing burden associated with adaptive optics scanning light ophthalmoscopy (AOSLO), we have developed an open-source, automated AOSLO image processing pipeline with both "live" and "full" modes....
7.
Italiano A, Miller Jr W, Blay J, Gietema J, Bang Y, Mileshkin L, et al.
Invest New Drugs
. 2021 Jun;
39(6):1587-1597.
PMID: 34180037
Aim The oral MDM2 antagonist idasanutlin inhibits the p53-MDM2 interaction, enabling p53 activation, tumor growth inhibition, and increased survival in xenograft models. Methods We conducted a Phase I study of...
8.
Latif A, Newcombe A, Li S, Gilroy K, Robertson N, Lei X, et al.
Nat Commun
. 2021 Jan;
12(1):241.
PMID: 33431824
Acute myeloid leukemia (AML) is a typically lethal molecularly heterogeneous disease, with few broad-spectrum therapeutic targets. Unusually, most AML retain wild-type TP53, encoding the pro-apoptotic tumor suppressor p53. MDM2 inhibitors...
9.
Yee K, Papayannidis C, Vey N, Dickinson M, Kelly K, Assouline S, et al.
Leuk Res
. 2020 Dec;
100:106489.
PMID: 33302031
The prognosis remains poor for patients with relapsed or refractory (r/r) acute myeloid leukemia; thus, novel therapies are needed. We evaluated idasanutlin-a new, potent murine double minute 2 antagonist-alone or...
10.
Konopleva M, Martinelli G, Daver N, Papayannidis C, Wei A, Higgins B, et al.
Leukemia
. 2020 Jul;
34(11):2858-2874.
PMID: 32651541
Targeting the interaction between tumor suppressor p53 and the E3 ligase MDM2 represents an attractive treatment approach for cancers with wild-type or functional TP53. Indeed, several small molecules have been...